Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet Extension Study in Pediatric SHPT
NCT02341417Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Number of Participants With Adverse Events at 32 weeks. Started Jun 2015; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02341417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341417.